Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

Kidney Cancer Research Bureau21 enrolled

Overview

Aim of the FavorAx study is to evaluate preliminary efficacy and safety of Axitinib in metastatic renal cell carcinoma patients with favorable IMDC prognostic factors who had progressed on sunitinib or pazopanib in the first-line setting.

Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit. The trial of comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) was an international randomized Phase III study designed for registration purposes. This trial randomized 723 metastatic renal cell carcinoma patients with any prognostic features to axitinib or sorafenib in the second-line setting and demonstrated significant clinical benefit of axitinib. Aim of present FavorAx study is to evaluate preliminary efficacy and safety of Axitinib in metastatic renal cell carcinoma patients with favorable IMDC prognostic factors who had progressed on sunitinib or pazopanib in the first-line setting.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Carcinoma, Renal Cell Clear Cell Renal Cell Carcinoma

Interventions

axitinibDRUG

Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Principle Inclusion Criteria: * Histologic confirmation of Renal cell carcinoma with a clear cell component * Patients must have measurable disease * Previous treatment with sunitinib or pazopanib * Favorable prognosis according to IMDC criteria * Must have available tumor tissue for submission * Subjects must also meet various laboratory parameters for inclusion * Patients must give written informed consent prior to initiation of therapy Exclusion Criteria: * Any underlying medical condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events * Patients who have history of uncompensated diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.

Locations (15)

Demchenkova Marina Viktorovna

Irkutsk, Russia

Semenov Andrey Vladimirovich

Ivanovo, Russia

Mikhailova Nadezhda Vasilievna

Kazan', Russia

Outcomes

Primary Outcomes

Progression-free survival

Time frame: 10 months

Secondary Outcomes

Objective response rate

Time frame: 24 months

Overall survival

Time frame: 24 months

Rate of treatment-related serious adverse events

Number of participants with treatment-related serious adverse events as assessed by CTCAE v4.0

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.